Emerging Biomarkers Have Potential to Refine Patient Selection, Improve Immunotherapy Strategies
+more
Drs. Marina Chiara Garassino, Sulin Wu, and Faith Abodunrin offer insights from the RELATIVITY-104 and GALAXIES Lung-201 Trials. Read more
Promising results from the phase III IMforte trial reveal a potential first-line therapy for patients with ES-SCLC. Read more
Prof. Benjamin Besse said the TKI showed encouraging clinical activity in patients who were heavily pre-treated. Read more
Dr. Alexander Drilon said most patients with ALK-positive NSCLC treated with NVL-655 showed disease regression and deep responses. Read more
Dr. Benjamin Besse recently discussed detailed findings from the now discontinued CARMEN-LC03 trial. Read more
Dr. Hidehito Horinouchi said treatment with Teliso-V demonstrated promising and durable responses in Asian cohort, particularly those with high c-Met expression. Read more
Dr. Jacob Sands presented findings that show a progression-free survival advantage for Dato-DXd versus docetaxel in the non-squamous cohort. Read more
The session will also include late-breaking data from HARMONi-2, NeoCOAST-2, and TROPION-Lung01 as well as an address from IASLC President Dr. Paul Van Schil. Read more
Drs. Jyoti Patel and Khyati Somayaji Dasika say the increased burden of lung cancer on women underscores the necessity for gender-sensitive approaches in healthcare policy, research, and clinical practice. Read more
While the study did not meet its primary endpoint of overall survival, it did demonstrate a significant benefit in overall and progression-free survival in the non-epithelioid patient population. Read more